ANDA 206122, held by Sciegen Pharms. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 206122 (Bupropion Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Aug 17, 2016, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bupropion Hydrochloride150MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Nov 6, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 13, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 13, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 13, 2021 | Supplement 7Manufacturing | Approved | None posted |
| Jun 30, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 17, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters